Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHV02 Nipah Vaccine Phase 1 Study
NCT05178901Phase 1Completed
- Sponsor
- Public Health Vaccines LLC
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PHV02 in Nipah virus infection (NiV) (6 arms), sponsored by Public Health Vaccines LLC. Primary endpoints: Number of participants with treatment-related adverse events as assessed by the Toxicity Grading Scale at 42 days and Number of participants with Nipah-specific antibody and neutralizing antibody responses at 29 days. Started Jan 2022; status: completed.
02
Drugs
PHV02
03
Conditions
Nipah virus infection (NiV)
Beyond the preview
Go deeper on NCT05178901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178901.